Therapeutic Trem2 activation ameliorates amyloid-beta deposition and improves cognition in the 5XFAD model of amyloid deposition

BACKGROUND: Triggering receptor expressed on myeloid cell-2 (TREM2) is a lipid and lipoprotein binding receptor expressed by cells of myeloid origin. Homozygous TREM2 mutations cause early onset progressive presenile dementia while heterozygous, point mutations triple the risk of Alzheimer’s disease...

Descripción completa

Detalles Bibliográficos
Autores principales: Price, Brittani R., Sudduth, Tiffany L., Weekman, Erica M., Johnson, Sherika, Hawthorne, Danielle, Woolums, Abigail, Wilcock, Donna M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7427742/
https://www.ncbi.nlm.nih.gov/pubmed/32795308
http://dx.doi.org/10.1186/s12974-020-01915-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7427742/
https://www.ncbi.nlm.nih.gov/pubmed/32795308
http://dx.doi.org/10.1186/s12974-020-01915-0

Ejemplares similares